Yangtze River Pharmacy Group Seeking Collaboration Opportunities At Zhangjiang Pharma Valley

In the afternoon on February 27th, the Deputy General Manager Sun Tianjiang and Dean of Jiangsu Taizhou Institute of Materia Medica Hong Xingguo visited several R&D enterprises in the purpose of seeking collaboration in new drug development and R&D outsourcing, including Shanghai AQBioPharma Co., Ltd, 2Y-Chem, Ltd and Medicilon. Initial intention of collaboration had been interchanged during those visits. PDBPA has accompanied the guests during the whole period of visit.

Yangtze River Pharmacy Group established in 1971 is a private-owned Pharmaceutical enterprise with integrated capability of manufacturing, merchandise and R&D. The headquarter was located in Taizhou Jiangsu Province, with five branches including Shanghai Haini, Beijing Haiyan, Guangzhou Hairui ,Chengdu Hairong as well as Nanjing Hailin. Yangtze River Pharmacy Group is one of the top-10 Chinese Pharmaceutical enterprises. The product lines have covered the area of Antibiotics, digestive system drugs, circulatory drugs, anticancer drugs, antipyretic analgesics etc. with More than 10 series, over 10 kinds of formulations, more than 100 specifications. The annual revenue of sales reached 13 billion RMB and is estimated to grow to 15 billion RMB
 
As to know, Yangtze River Pharmacy Group is ready to establish several R&D centers and have started the collaboration with scientific institutes and universities for establishing new drug R&D platform, meanwhile, it is paying more attention to the collaboration with domestic R&D outsourcing companies.
 
Since domestic pharmaceuticals pay more attention to R&D, companies like Yangtze River Pharmacy Group are willing to contact with domestic R&D outsourcing companies, which will definitely be the new trend of outsourcing industry development.
 
CEO of Medicilon Dr Chen Chunlin mentioned during their visit that the local R&D outsourcing enterprises were more mature than ever before. Their R&D methods have no significant difference when comparing with globalize pharmaceuticals.. In consequence, they are willing to collaborate with domestic pharmaceuticals in new drug development.

 

[关闭窗口] [打印]